A Pilot Study of Continuous Subcutaneous Pramlintide Infusion Therapy in Patients With Type 1 Diabetes

IDDM Clinical Trial

Official title:

A Pilot Study to Assess the Pharmacokinetics, Pharmacodynamics and Safety/Tolerability of Pramlintide Acetate When Administered by Subcutaneous Infusion in a Basal-Bolus Manner as an Adjunct to Continuous Subcutaneous Insulin Infusion Therapy in Patients With Type 1 Diabetes

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00502138
• Other study ID #: Pramlintide Infusion in IDDM
• Status: Completed
• Phase: Phase 4
• First received: July 16, 2007
• Last updated: January 15, 2013
• Start date: July 2007
• Est. completion date: January 2008

Study information

• Verified date: January 2013
• Source: University Diabetes & Endocrine Consultants
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug AdministrationUnited States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

This research project will investigate the effects of pramlintide (Symlin) given by continuous subcutaneous (under the skin) infusion throughout the day and night, along with meal doses similar to those injected during conventional pramlintide (Symlin) treatment, delivered using a second insulin pump, in subjects with inadequately controlled type I diabetes mellitus who are already using insulin pump therapy. Study participants will wear two pumps for a four month period, taking insulin in their usual manner and pramlintide (Symlin) in a similar basal/bolus fashion. Continuous glucose monitors will be worn on three occasions during the study to assess blood glucose responses to continuous pramlintide (Symlin) treatment.

Description:

DESCRIPTION OF STUDY:

To participate in the study, you must have Type I diabetes mellitus and be taking insulin using an insulin pump, and have a hemoglobin A1c level between 7.0% and 10.0%. You will not be permitted to participate in the study if you have taken pramlintide (Symlin) during the previous three months. The study will consist of seven visits to the Study Center over a four-month period. Subjects will undergo meal tolerance testing at beginning and end of study period. Continuous blood glucose monitoring will be performed on three occasions during the study.

Pramlintide will be begun at a single basal rate of 1.5 units/hr. Bolus therapy will be begun thereafter per standard manufacturer protocol. Subjects will be monitored for three months on basal-bolus pramlintide therapy.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 12
• Est. completion date: January 2008
• Est. primary completion date: January 2008
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

1. Type 1 diabetes of at least one year duration;

2. Treated with CSII therapy for at least 6 months;

3. Age 18 to 70 years, inclusive;

4. A1C >7.0 and =10% as screening;

5. BMI =35 kg/m2;

6. Stable insulin dose (±10%) for at least 3 months prior to screening;

7. If female, has a negative urine pregnancy test at screening;

8. If female and of childbearing potential, practicing and willing to continue to using appropriate contraception to ensure that pregnancy does not occur during the study;

9. Able to understand and sign the required study documents and comply with the protocol requirements

Exclusion Criteria:

1. Is poorly compliant with the currently prescribed insulin regimen, as determined by the investigator;

2. Has any significant medical condition, laboratory findings, or medical history that may affect successful completion of the study and/or personal well-being;

3. If female and if of childbearing potential, is pregnant, lactating, or planning to become pregnant;

4. Has experienced recurrent severe hypoglycemia requiring assistance during the past 6 months;

5. Has a history of hypoglycemia unawareness;

6. Has a confirmed diagnosis of gastroparesis;

7. Requires the use of drugs that stimulate gastrointestinal motility;

8. Is receiving medications known to interfere with glycemic control (i.e. glucocorticoids);

9. Has been treated with any oral antidiabetic agent or exenatide within 3 months of screening visit;

10. Has been treated with pramlintide within 3 months of screening visit;

11. Has received an investigational drug within 3 month of screening visit;

12. Is currently participating in a clinical trial

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• IDDM

Intervention

Drug:
• Continuous Pramlintide infusion
pramlintide injection, 9 mcg/hr plus 60 mcg premeal boluses

Locations

Country	Name	City	State
United States	University Diabetes & Endocrine Consultants	Chattanooga	Tennessee

Sponsors (2)

Lead Sponsor	Collaborator
University Diabetes & Endocrine Consultants	Amylin Pharmaceuticals, LLC.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Fasting and postprandial pramlintide pharmacokinetics		Four months	No
Secondary	Hemoglobin A1c, body weight, blood glucose variability, patient satisfaction		four months	Yes
Secondary	Hemoglobin A1c		16 weeks	No